ChinaDrugStatus
Commercial Health Insurance Innovative Drug List (商业健康保险创新药品目录)

2026 Commercial Insurance Innovative Drug List

Complete 28-drug directory published Nov 14, 2026 (effective Jan 1, 2027), audited against the 19-drug 2025 baseline edition: 12 newly added, 1 indication expanded, 15 retained, and 3 removed from the 2025 list (2 graduated into basic NRDL).

Policy scope note: Inclusion in the NHSA Commercial Health Insurance Innovative Drug List indicates national catalog listing for commercial insurer reference (basic medical insurance funds do not reimburse these drugs). Actual patient reimbursement depends on individual commercial health insurance policy contracts.

Complete 2026 Directory (28 drugs)

No. & BrandGeneric NameMAH & Authorized EntityListed Indication ScopeValidity & StatusSource
#1
戈芮宁
Retained from 2025
Velaglucerase beta for Injection
注射用维拉苷酶β
北海康成(上海)生物科技有限公司

Long-term enzyme replacement therapy (ERT) for adolescents ≥12y and adults with type I and type III Gaucher disease.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.2
Verified 2026-11-21
#2
Revestive / 瑞唯抒
Retained from 2025
Teduglutide for Injection
注射用替度格鲁肽
Takeda Pharmaceuticals International AG Ireland Branch
Authorized: 武田(中国)国际贸易有限公司

Short bowel syndrome (SBS) in adults and children ≥1y who are stable following intestinal adaptation and dependent on parenteral support.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.2
Verified 2026-11-21
#3
Cablivi / 可倍力
Added 2026
Caplacizumab for Injection
注射用卡拉西珠单抗
Ablynx NV
Authorized: 赛诺菲(中国)投资有限公司上海分公司

Acquired thrombotic thrombocytopenic purpura (aTTP/iTTP) in adults and adolescents ≥12y (≥40 kg) combined with plasma exchange and immunosuppression.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.2
Verified 2026-11-21
#4
信玖凝
Added 2026
Dalnacogene ponparvovec Injection
波哌达可基注射液
上海信致医药科技有限公司

Moderate-to-severe hemophilia B (congenital Factor IX deficiency) in adult patients.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.2
Verified 2026-11-21
#5
Ziihera / 百赫安
Retained from 2025
Zanidatamab for Injection
注射用泽尼达妥单抗
百济神州(苏州)生物科技有限公司
Authorized: 百济神州(北京)生物科技有限公司

Previously treated HER2-high (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.2
Verified 2026-11-21
#6
Elrexfio / 易瑞欧
Retained from 2025
Elranatamab Injection
埃纳妥单抗注射液
Pfizer Inc.
Authorized: 辉瑞投资有限公司

Adult relapsed or refractory multiple myeloma after ≥3 prior lines (including a PI, IMiD, and anti-CD38 mAb).

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.2
Verified 2026-11-21
#7
Qarziba / 凯泽百
Retained from 2025
Dinutuximab beta Injection
达妥昔单抗β注射液
Recordati Netherlands B.V.
Authorized: 百济神州(北京)生物科技有限公司

High-risk neuroblastoma in patients ≥12 months after induction chemo + myeloablative therapy/SCT, or relapsed/refractory neuroblastoma.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.2
Verified 2026-11-21
#8
Danyelza / 达佑泽
Retained from 2025
Naxitamab Injection
那西妥单抗注射液
Y-mAbs Therapeutics, Inc.
Authorized: 赛生医药江苏有限公司

Relapsed/refractory high-risk neuroblastoma in bone or bone marrow (children ≥1y and adults) in combination with GM-CSF.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.3
Verified 2026-11-21
#9
Talvey / 拓立珂
Retained from 2025
Talquetamab Injection
塔奎妥单抗注射液
Janssen-Cilag International NV
Authorized: 强生制药有限公司

Monotherapy for adult relapsed or refractory multiple myeloma after ≥3 prior lines (PI, IMiD, and anti-CD38 antibody).

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.3
Verified 2026-11-21
#10
Yervoy / 逸沃
Retained from 2025
Ipilimumab Injection
伊匹木单抗注射液
Bristol-Myers Squibb Pharma EEIG
Authorized: 百时美施贵宝(中国)投资有限公司

In combination with nivolumab: (1) 1L unresectable non-epithelioid MPM; (2) 1L unresectable/metastatic MSI-H/dMMR CRC; (3) 1L unresectable/advanced HCC.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.3
Verified 2026-11-21
#11
Poteligeo / 惠尔金
Added 2026
Mogamulizumab Injection
莫格利珠单抗注射液
Kyowa Kirin Co.,Ltd.
Authorized: 维健(中国)制药有限公司

Adult relapsed or refractory Sézary syndrome (SS) or advanced (stage III/IV) mycosis fungoides (MF) after prior systemic therapy.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.3
Verified 2026-11-21
#12
Yescarta / 奕凯达
Retained from 2025
Axicabtagene ciloleucel Injection
阿基仑赛注射液
复星凯瑞(上海)生物科技有限公司

CD19 CAR-T for adult r/r LBCL refractory to or relapsed ≤12 months after 1L immunochemotherapy (conditional), and ≥3L adult r/r LBCL.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.3
Verified 2026-11-21
#13
源瑞达
Indication Expanded
Inaticabtagene autoleucel Injection
纳基奥仑赛注射液
Full drug profile →
合源生物科技股份有限公司

Expanded in 2026: adult r/r B-ALL plus ≥3L adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL).

Jan 1, 2026 – Dec 31, 2027
Announced · Effective Jan 1, 2027
NHSA · PDF p.3
Verified 2026-11-21
#14
Fucaso / 福可苏
Retained from 2025
Equecabtagene autoleucel Injection
伊基奥仑赛注射液
南京驯鹿生物医药有限公司

Adult relapsed or refractory multiple myeloma progressing after ≥3 prior lines (including at least one PI and IMiD).

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.3
Verified 2026-11-21
#15
赛恺泽
Retained from 2025
Zevorcabtagene autoleucel Injection
泽沃基奥仑赛注射液
恺兴生命科技(上海)有限公司

Adult relapsed or refractory multiple myeloma progressing after ≥3 prior lines (including at least one PI and IMiD).

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.3
Verified 2026-11-21
#16
恺力美
Added 2026
Satricabtagene autoleucel Injection
舒瑞基奥仑赛注射液
恺兴生命科技(上海)有限公司

CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after ≥2 prior failed lines.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.3
Verified 2026-11-21
#17
普利得凯
Added 2026
Pricabtagene autoleucel Injection
普基奥仑赛注射液
重庆精准生物技术有限公司

CD19-positive refractory or relapsed B-cell acute lymphoblastic leukemia in patients aged 3–21 years.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.3
Verified 2026-11-21
#18
Hicara / 恒凯莱
Added 2026
Ranicabtagene autoleucel Injection
雷尼基奥仑赛注射液
上海恒润达生生物科技股份有限公司

Adult relapsed or refractory LBCL after ≥2 prior lines of systemic therapy (DLBCL NOS, transformed FL, HGBL with MYC/BCL2 rearrangements, HGBL NOS).

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-21
#19
普罗仙安
Retained from 2025
Para-toluenesulfonamide Injection
甲苯磺酰胺注射液
天津红日健达康医药科技有限公司

Adult central non-small cell lung cancer to relieve severe central airway obstruction.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.4
Verified 2026-11-21
#20
Zepzelca / 赞必佳
Retained from 2025
Lurbinectedin for Injection
注射用芦比替定
PharmaMar AG
Authorized: 南京绿叶制药有限公司

Adult metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.4
Verified 2026-11-21
#21
Crysvita / 麟平
Added 2026
Burosumab Injection
布罗索尤单抗注射液
Kyowa Kirin Co.,Ltd.
Authorized: 维健(中国)制药有限公司

(1) X-linked hypophosphatemia (XLH) in adults and children ≥1y; (2) FGF23-related hypophosphatemia in adult tumor-induced osteomalacia (TIO).

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-21
#22
Kisunla / 记能达
Retained from 2025
Donanemab Injection
多奈单抗注射液
Eli Lilly and Company
Authorized: 礼来贸易有限公司

Mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease dementia.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.4
Verified 2026-11-21
#23
Leqembi / 乐意保
Retained from 2025
Lecanemab Injection
仑卡奈单抗注射液
Eisai Inc.
Authorized: 卫材(中国)药业有限公司

Mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease dementia.

Jan 1, 2026 – Dec 31, 2027
Effective
NHSA · PDF p.4
Verified 2026-11-21
#24
Wainua / 万诺维
Added 2026
Eplontersen Sodium Injection
依普隆特生钠注射液
Full drug profile →
AstraZeneca AB
Authorized: 阿斯利康(无锡)贸易有限公司

Polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-21
#25
Qalsody / 凯盛迪
Added 2026
Tofersen Injection
托夫生注射液
Full drug profile →
Biogen MA Inc.
Authorized: 渤健生物科技(上海)有限公司

Adult amyotrophic lateral sclerosis (ALS) associated with a SOD1 gene mutation.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-21
#26
—
Added 2026
Diazoxide Oral Suspension
二氮嗪口服混悬液
宿州亿帆药业有限公司

Congenital hyperinsulinemic hypoglycemia.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-21
#27
SIR-Spheres
Added 2026
Yttrium [90Y] Microspheres Injection
钇[90Y]微球注射液
Sirtex Medical Pty Ltd
Authorized: 武汉远大制药集团销售有限公司

Unresectable colorectal liver metastases after failure of standard therapy.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-21
#28
Pluvicto / 派威妥
Added 2026
Lutetium (177Lu) vipivotide tetraxetan Injection
镥[177Lu]特昔维匹肽注射液
Full drug profile →
Novartis Pharma Schweiz AG
Authorized: 诺华医药科技(浙江)有限公司

Adult PSMA-positive mCRPC post-ARPI (suitable to delay chemotherapy) or post-ARPI and taxane chemotherapy.

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.5
Verified 2026-11-21

2025 Commercial List Entries Not Carried Into 2026 (3)

Verified by diffing the official 2025 Commercial List PDF (19 drugs) against the 2026 Commercial List PDF (28 drugs). Two therapies graduated directly into the 2026 basic NRDL.

2025 No. & BrandGeneric Name2026 OutcomeMAH2025 Source
2025 #2
海普益
Sapropterin dihydrochloride
盐酸沙丙蝶呤片
Graduated to 2026 Basic NRDL (#42)

Reimbursed under basic medical insurance effective Jan 1, 2027.

Shandong New Time Pharmaceutical Co., Ltd.NHSA · PDF p.2
2025 #12
Carteyva / 倍诺达
Relmacabtagene autoleucel
瑞基奥仑赛注射液
Graduated to 2026 Basic NRDL (#297)

Reimbursed under basic medical insurance effective Jan 1, 2027.

JW Therapeutics (Shanghai) Co., Ltd.NHSA · PDF p.4
2025 #16
Tazverik / 达唯珂
Tazemetostat hydrobromide
氢溴酸他泽司他片
Omitted from 2026 Commercial List

Not listed in 2026 Commercial List or 2026 NRDL.

Epizyme, Inc.NHSA · PDF p.4